

# James H McMahon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7880019/publications.pdf>

Version: 2024-02-01

78  
papers

3,284  
citations

201385

27  
h-index

161609

54  
g-index

80  
all docs

80  
docs citations

80  
times ranked

5809  
citing authors

#	ARTICLE	IF	CITATIONS
1	Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy. <i>PLoS Pathogens</i> , 2014, 10, e1004473.	2.1	437
2	Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. <i>Lancet</i> , The, 2019, 393, 143-155.	6.3	265
3	Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. <i>Science Immunology</i> , 2020, 5, .	5.6	244
4	Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. <i>Lancet HIV</i> ,the, 2015, 2, e520-e529.	2.1	213
5	Pharmacy Adherence Measures to Assess Adherence to Antiretroviral Therapy: Review of the Literature and Implications for Treatment Monitoring. <i>Clinical Infectious Diseases</i> , 2011, 52, 493-506.	2.9	139
6	BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection. <i>Cell</i> , 2021, 184, 2167-2182.e22.	13.5	131
7	Long-term Virological Outcomes of First-Line Antiretroviral Therapy for HIV-1 in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2015, 61, 1453-1461.	2.9	129
8	Monkeypox infection presenting as genital rash, Australia, May 2022. <i>Eurosurveillance</i> , 2022, 27, .	3.9	116
9	Viral suppression after 12 months of antiretroviral therapy in low- and middle-income countries: a systematic review. <i>Bulletin of the World Health Organization</i> , 2013, 91, 377-385E.	1.5	115
10	Integrated immune dynamics define correlates of COVID-19 severity and antibody responses. <i>Cell Reports Medicine</i> , 2021, 2, 100208.	3.3	115
11	Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. <i>Lancet HIV</i> ,the, 2018, 5, e211-e220.	2.1	108
12	Barriers and strategies to achieve a cure for HIV. <i>Lancet HIV</i> ,the, 2018, 5, e317-e328.	2.1	99
13	The HIV care cascade: a systematic review of data sources, methodology and comparability. <i>Journal of the International AIDS Society</i> , 2015, 18, 20634.	1.2	92
14	Broad activation of latent HIV-1 in vivo. <i>Nature Communications</i> , 2016, 7, 12731.	5.8	65
15	HIV Drug Resistance Early Warning Indicators in Cohorts of Individuals Starting Antiretroviral Therapy Between 2004 and 2009: World Health Organization Global Report From 50 Countries. <i>Clinical Infectious Diseases</i> , 2012, 54, S280-S289.	2.9	62
16	Concomitant medication polypharmacy, interactions and imperfect adherence are common in Australian adults on suppressive antiretroviral therapy. <i>Aids</i> , 2018, 32, 35-48.	1.0	60
17	Poverty, Hunger, Education, and Residential Status Impact Survival in HIV. <i>AIDS and Behavior</i> , 2011, 15, 1503-1511.	1.4	55
18	Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial. <i>Lancet HIV</i> ,the, 2020, 7, e16-e26.	2.1	53

#	ARTICLE	IF	CITATIONS
19	Repeated Assessments of Food Security Predict CD4 Change in the Setting of Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 58, 60-63.	0.9	46
20	Clinical care of pregnant and postpartum women with COVID-19: Living recommendations from the National COVID-19 Clinical Evidence Taskforce. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2020, 60, 840-851.	0.4	36
21	Diverse effects of interferon alpha on the establishment and reversal of HIV latency. <i>PLoS Pathogens</i> , 2020, 16, e1008151.	2.1	36
22	Effects of Physical Tracing on Estimates of Loss to Follow-Up, Mortality and Retention in Low and Middle Income Country Antiretroviral Therapy Programs: A Systematic Review. <i>PLoS ONE</i> , 2013, 8, e56047.	1.1	35
23	The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial. <i>Lancet HIV</i> , 2018, 5, e221-e230.	2.1	34
24	Thrombospondin-1 is a critical modulator in non-alcoholic steatohepatitis (NASH). <i>PLoS ONE</i> , 2019, 14, e0226854.	1.1	34
25	Clinical trials of antiretroviral treatment interruption in HIV-infected individuals. <i>Aids</i> , 2019, 33, 773-791.	1.0	34
26	Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial. <i>Lancet HIV</i> , 2017, 4, e486-e494.	2.1	31
27	Population Pharmacokinetics and Pharmacodynamics of Disulfiram on Inducing Latent HIV-1 Transcription in a Phase IIb Trial. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 692-702.	2.3	29
28	Is hospital-in-the-home (HITH) treatment of bacterial endocarditis safe and effective?. <i>Scandinavian Journal of Infectious Diseases</i> , 2008, 40, 40-43.	1.5	27
29	Experiences and expectations of participants completing an HIV cure focused clinical trial. <i>Aids</i> , 2015, 29, 248-250.	1.0	27
30	Perspectives on Analytical Treatment Interruptions in People Living with HIV and Their Health Care Providers in the Landscape of HIV Cure-Focused Studies. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 260-267.	0.5	24
31	Multiply spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following reversal of HIV latency. <i>EBioMedicine</i> , 2021, 65, 103241.	2.7	24
32	The Impact of the COVID-19 Pandemic on People Living with HIV in Victoria, Australia. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 322-328.	0.5	21
33	Clinic Network Collaboration and Patient Tracing to Maximize Retention in HIV Care. <i>PLoS ONE</i> , 2015, 10, e0127726.	1.1	21
34	SARS-CoV-2 infection results in immune responses in the respiratory tract and peripheral blood that suggest mechanisms of disease severity. <i>Nature Communications</i> , 2022, 13, 2774.	5.8	21
35	Pharmacy and Self-Report Adherence Measures to Predict Virological Outcomes for Patients on Free Antiretroviral Therapy in Tamil Nadu, India. <i>AIDS and Behavior</i> , 2013, 17, 2253-2259.	1.4	17
36	Time from HIV diagnosis to commencement of antiretroviral therapy as an indicator to supplement the HIV cascade: Dramatic fall from 2011 to 2015. <i>PLoS ONE</i> , 2017, 12, e0177634.	1.1	17

#	ARTICLE	IF	CITATIONS
37	The impact of immune checkpoint therapy on the latent reservoir in HIV-infected individuals with cancer on antiretroviral therapy. <i>Aids</i> , 2021, 35, 1631-1636.	1.0	16
38	Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells Ex Vivo in People Living with HIV on Antiretroviral Therapy. <i>Journal of Immunology</i> , 2022, 208, 54-62.	0.4	16
39	90-90-90: how do we get there?. <i>Lancet HIV</i> , 2014, 1, e10-e11.	2.1	14
40	Torsades de pointes in a patient receiving fluconazole for cerebral cryptococcosis. <i>American Journal of Health-System Pharmacy</i> , 2008, 65, 619-623.	0.5	13
41	Post-treatment control in an adult with perinatally acquired HIV following cessation of antiretroviral therapy. <i>Aids</i> , 2017, 31, 1344-1346.	1.0	13
42	A clinical trial of non-invasive imaging with an anti-HIV antibody labelled with copper-64 in people living with HIV and uninfected controls. <i>EBioMedicine</i> , 2021, 65, 103252.	2.7	12
43	Identification of 5-Substituted 2-Acylaminothiazoles That Activate Tat-Mediated Transcription in HIV-1 Latency Models. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 5148-5175.	2.9	11
44	The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , 2020, 21, 646.	0.7	11
45	Impact of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy with Sezary syndrome. <i>Aids</i> , 2017, 31, 1839-1845.	1.0	10
46	Yoghurt consumption and damaged colonic mucosa: A case of <i>Lactococcus lactis</i> liver abscess in an immunocompetent patient. <i>Scandinavian Journal of Infectious Diseases</i> , 2006, 38, 739-741.	1.5	9
47	Risk factors for mortality during antiretroviral therapy in older populations in resource-limited settings. <i>Journal of the International AIDS Society</i> , 2016, 19, 20665.	1.2	9
48	No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapy. <i>Aids</i> , 2017, 31, 1137-1141.	1.0	9
49	Acceptability, motivation and the prospect of cure for people living with HIV and their healthcare providers in HIV cure-focused treatment interruption studies. <i>AIDS Research and Therapy</i> , 2020, 17, 65.	0.7	9
50	Leveraging the advances in HIV for COVID-19. <i>Lancet</i> , 2020, 396, 943-944.	6.3	8
51	Paying the price in an era of HIV treatment as prevention: a retrospective study of the cost burden of HIV treatment for people living with HIV in Victoria, Australia. <i>Sexual Health</i> , 2015, 12, 34.	0.4	7
52	The RNA-Binding Proteins SRP14 and HMGB3 Control HIV-1 Tat mRNA Processing and Translation During HIV-1 Latency. <i>Frontiers in Genetics</i> , 2021, 12, 680725.	1.1	7
53	Neurotoxicity with high-dose disulfiram and vorinostat used for HIV latency reversal. <i>Aids</i> , 2022, 36, 75-82.	1.0	7
54	An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , 2020, 21, 847.	0.7	6

#	ARTICLE	IF	CITATIONS
55	Cutting Edge: SARS-CoV-2 Infection Induces Robust Germinal Center Activity in the Human Tonsil. <i>Journal of Immunology</i> , 2022, , ji2101199.	0.4	6
56	Routine versus Targeted Viral Load Strategy among Patients Starting Antiretroviral in Hanoi, Vietnam. <i>Journal of the International AIDS Society</i> , 2019, 22, e25258.	1.2	5
57	A New Method for Estimating the Incidence of Infectious Diseases. <i>American Journal of Epidemiology</i> , 2021, 190, 1386-1395.	1.6	5
58	Bringing evidence from press release to the clinic in the era of COVID-19. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 547-549.	1.3	5
59	Integrase-resistant HIV in an antiretroviral-naïve patient in Australia. <i>Aids</i> , 2017, 31, 598-600.	1.0	4
60	Improvements in transition times through the HIV cascade of care among gay and bisexual men with a new HIV diagnosis in New South Wales and Victoria, Australia (2012â€“19): a longitudinal cohort study. <i>Lancet HIV</i> , 2021, 8, e623-e632.	2.1	4
61	Disseminated nocardiosis with adrenal abscess masquerading as metastatic adrenal cancer in an immunocompetent adult. <i>ANZ Journal of Surgery</i> , 2021, 91, E396-E398.	0.3	4
62	Histologic, immunohistochemical, microbiological, molecular biological and ultrastructural characterization of pulmonary tularemia. <i>Pathology Research and Practice</i> , 2011, 207, 63-66.	1.0	3
63	Targets for intervention to improve virological outcomes for patients receiving free antiretroviral therapy in Tamil Nadu, India. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2014, 26, 559-566.	0.6	3
64	Risk factors for unstructured treatment interruptions and association with survival in low to middle income countries. <i>AIDS Research and Therapy</i> , 2016, 13, 25.	0.7	3
65	Treatment of disseminated histoplasmosis in advanced HIV using itraconazole with increased bioavailability. <i>International Journal of STD and AIDS</i> , 2018, 29, 1448-1450.	0.5	3
66	Viral, inflammatory, and reservoir characteristics of posttreatment controllers. <i>Current Opinion in HIV and AIDS</i> , 2021, 16, 249-256.	1.5	3
67	Updated Australian guidance for health care providers about "undetectable = untransmittable" for HIV. <i>Medical Journal of Australia</i> , 2021, 215, 201.	0.8	3
68	Detection of Chimeric Cellular: HIV mRNAs Generated Through Aberrant Splicing in HIV-1 Latently Infected Resting CD4+ T Cells. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 855290.	1.8	3
69	Balancing Statistical Power and Risk in HIV Cure Clinical Trial Design. <i>Journal of Infectious Diseases</i> , 2022, 226, 236-245.	1.9	2
70	Recruiting people with HIV to an online self-management support randomised controlled trial: barriers and facilitators. <i>Sexual Health</i> , 2019, 16, 340.	0.4	1
71	Is it time for injectable antiretroviral therapy for HIV?. <i>Lancet, The</i> , 2020, 396, 1944-1946.	6.3	1
72	Successful treatment of disseminated <i>Mycobacterium simiae</i> infection in a patient with advanced HIV. <i>Aids</i> , 2021, 35, 157-158.	1.0	1

#	ARTICLE	IF	CITATIONS
73	IgG4-related disease masquerading as a fungating groin lesion in a patient with HIV and incomplete immune reconstitution. <i>Aids</i> , 2021, 35, 706-707.	1.0	1
74	Interrupting antiretroviral therapy in HIV cure trials during COVID-19: Adaptation to low transmission settings. <i>Journal of Virus Eradication</i> , 2021, 7, 100032.	0.3	1
75	Exploring sentinel conditions and the accrual sequence of multiple long-term condition multimorbidity using birth cohort and primary care data: an exploratory retrospective cohort study. <i>Lancet, The</i> , 2021, 398, S54.	6.3	1
76	Less frequent CD4 monitoring in virologically suppressed HIV. <i>Lancet HIV,the</i> , 2017, 4, e233-e234.	2.1	0
77	Early Outpatient Treatment of SARS-CoV-2 (COVID-19): A Comment. <i>American Journal of Medicine</i> , 2021, 134, e220-e221.	0.6	0
78	Acceptability of Injectable Antiretroviral Therapy in Australian Travelers With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, e13-e15.	0.9	0